Compounds of formula I

##STR00001##

a process for preparation of compounds of formula I; precursor compounds of formula II

##STR00002##

a process for preparation of precursor compounds of formula II; compounds of formula III

##STR00003##

a process for the preparation of compounds of formula IV from compounds of formula III

##STR00004##

and the use of compounds of formula I for the preparation of compounds of formula IV.

Compounds of formula I

##STR00001##

a process for preparation of compounds of formula I; precursor compounds of formula II

##STR00002##

a process for preparation of precursor compounds of formula II; compounds of formula III

##STR00003##

a process for the preparation of compounds of formula IV from compounds of formula III

##STR00004##

and the use of compounds of formula I for the preparation of compounds of formula IV.

Compounds of formula I

##STR00001##

a process for preparation of compounds of formula I; precursor compounds of formula II

##STR00002##

a process for preparation of precursor compounds of formula II; compounds of formula III

##STR00003##

a process for the preparation of compounds of formula IV from compounds of formula III

##STR00004##

and the use of compounds of formula I for the preparation of compounds of formula IV.

Disclosed is a fluorination method comprising providing an aryl fluorosulfonate and a fluorinating reagent to a reaction mixture; and reacting the aryl fluorosulfonate and the fluorinating reagent to provide a fluorinated aryl species. Also disclosed is a fluorination method comprising providing, a salt comprising a cation and an aryloxylate, and SO.sub.2F.sub.2 to a reaction mixture; reacting the SO.sub.2F.sub.2 and the ammonium salt to provide a fluorinated aryl species. Further disclosed a fluorination method comprising providing a compound having the structure ArOH to a reaction mixture; where A is an aryl or heteroaryl; providing SO.sub.2F.sub.2 to the reaction mixture; providing a fluorinating reagent to the reaction mixture; reacting the SO.sub.2F.sub.2, the fluorinating reagent and the compound having the structure ArOH to provide a fluorinated aryl species having the structure ArF.

Disclosed is a fluorination method comprising providing an aryl fluorosulfonate and a fluorinating reagent to a reaction mixture; and reacting the aryl fluorosulfonate and the fluorinating reagent to provide a fluorinated aryl species. Also disclosed is a fluorination method comprising providing, a salt comprising a cation and an aryloxylate, and SO.sub.2F.sub.2 to a reaction mixture; reacting the SO.sub.2F.sub.2 and the ammonium salt to provide a fluorinated aryl species. Further disclosed a fluorination method comprising providing a compound having the structure ArOH to a reaction mixture; where A is an aryl or heteroaryl; providing SO.sub.2F.sub.2 to the reaction mixture; providing a fluorinating reagent to the reaction mixture; reacting the SO.sub.2F.sub.2, the fluorinating reagent and the compound having the structure ArOH to provide a fluorinated aryl species having the structure ArF.

The present invention discloses an iron-based nitrogen doped graphene catalyst, process for preparation thereof and use of said catalyst in oxidant-free catalytic dehydrogenation of alcohols and amines to the corresponding carbonyl compounds, amines and N-heterocylic compounds with extraction of molecular hydrogen as the only by-product.

The present invention discloses an iron-based nitrogen doped graphene catalyst, process for preparation thereof and use of said catalyst in oxidant-free catalytic dehydrogenation of alcohols and amines to the corresponding carbonyl compounds, amines and N-heterocylic compounds with extraction of molecular hydrogen as the only by-product.

Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I:

##STR00001##

wherein R.sub.1 to R.sub.5 and X.sub.1 to X.sub.5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

Disclosed are compounds which are nuclear receptor modulators that can act as antagonists to the androgen receptor, for example, a compound of Formula I:

##STR00001##

wherein R.sub.1 to R.sub.5 and X.sub.1 to X.sub.5 are as described herein, as well as pharmaceutically acceptable salts, solvates, and stereoisomers thereof. Pharmaceutical compositions comprising such compounds, as well as methods of use, and treatment for cancers, including prostate cancers, other nuclear receptor mediated cancers, and other conditions, are also disclosed.

Compounds and compositions are disclosed that are useful for treating ophthalmic conditions caused by or related to production of toxic visual cycle products that accumulate in the eye, such as dry adult macular degeneration, as well as conditions caused by or related to the misfolding of mutant opsin proteins and/or the mis-localization of opsin proteins. Compositions of these compounds alone or in combination with other therapeutic agents are also described, along with therapeutic methods of using such compounds and/or compositions. Methods of synthesizing such agents are also disclosed.